Table 3.
Association between AFP changes with median log TOT on SOR and CPI.
| AFP category |
n SOR (n = 175) |
Median log of TOT a SOR | p b (Wilcoxon) SOR | p c (Kruskal–Wallis) SOR |
n CPI (n = 41) |
Median log of TOT
a
CPI |
p b (Wilcoxon) CPI |
p
c
(Kruskal–Wallis) CPI |
|---|---|---|---|---|---|---|---|---|
| Decrease | ||||||||
| ⩾20% | 58 | 5.19 | <0.001 | <0.001 | 12 | 5.63 | 0.002 | 0.004 |
| <20% | 66 | 4.54 | 16 | 3.91 | ||||
| NE | 51 | 4.78 | – | 13 | 4.22 | – | ||
| ⩾50% | 45 | 5.27 | <0.001 | <0.001 | 9 | 5.73 | <0.001 | <0.001 |
| <50% | 79 | 4.53 | 19 | 4.04 | ||||
| NE | 51 | 4.78 | – | 13 | 4.22 | – | ||
| Increase | ||||||||
| ⩾20% | 42 | 4.52 | 0.006 | 0.006 | 11 | 4.04 | 0.013 | 0.03 |
| <20% | 82 | 4.99 | 17 | 5.55 | ||||
| NE | 51 | 4.78 | – | 13 | 4.22 | – | ||
| ⩾50% | 29 | 4.51 | 0.02 | 0.02 | 7 | 4.04 | 0.015 | 0.03 |
| <50% | 95 | 4.89 | 21 | 5.52 | ||||
| NE | 51 | 4.78 | – | 13 | 4.22 | – |
a
TOT (in days) was log-transformed to normalize the distribution.
b
Kruskal–Wallis test was used for across-group comparisons.
c
Wilcoxon rank sum test was used for pairwise comparisons (excluding the non-evaluable patients).
APE, alpha-fetoprotein; CPI, checkpoint inhibitor; NE, not evaluable; SOR, sorafenib; TOT, time on treatment.